Targeting AR Variant-coactivator Interactions to Exploit Prostate Cancer Vulnerabilities
Meghan Rice
Molecular cancer research : MCR, 2017
View PDFchevron_right
Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer
Yao ZHU
Scientific reports, 2015
View PDFchevron_right
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Daniel Nava Rodrigues
Clinical Cancer Research, 2020
View PDFchevron_right
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
Juan J. Diaz-Mochon
Cancers, 2021
View PDFchevron_right
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
Alberto D'Angelo
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Karen Knudsen
Trends in Endocrinology & Metabolism, 2010
View PDFchevron_right
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Nane Kuznik
Cancer cell, 2019
View PDFchevron_right
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Ganesh Raj
Nucleic Acids Research, 2015
View PDFchevron_right
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer
Inna Shyshynova
Cell Cycle, 2009
View PDFchevron_right
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Karen Knudsen
Clinical Cancer Research, 2009
View PDFchevron_right
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
Brooke Mccollum
Neoplasia, 2020
View PDFchevron_right
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Charles Sawyers
Proceedings of the National Academy of Sciences, 2010
View PDFchevron_right
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer
Ilsa Coleman
Neoplasia (New York, N.Y.), 2013
View PDFchevron_right
Non-nuclear AR Signaling in Prostate Cancer
Anna Tesei
Frontiers in Chemistry
View PDFchevron_right
Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance
Yingming Li
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017
View PDFchevron_right
A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
Jonathan Melamed
Cancer Research, 2009
View PDFchevron_right
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
Wout Devlies
Cancers
View PDFchevron_right
AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
Alwyn Dart
Endocrine Connections, 2020
View PDFchevron_right
960 ASC-J9® Suppresses Castration-Resistant Prostate Cancer Growth via Degradation of Full-Length and Splice Variant Androgen Receptors
Tatsuo Tochigi
The Journal of Urology, 2012
View PDFchevron_right
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Norbert Grundmann
Biomarker Research
View PDFchevron_right
Mechanisms of prostate cancer cell survival after inhibition of AR expression
oskar rokhlin
Journal of Cellular Biochemistry, 2009
View PDFchevron_right
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
Yingming Li
Proceedings of the National Academy of Sciences, 2013
View PDFchevron_right
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Yanfeng Qi
Oncotarget, 2014
View PDFchevron_right
Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target
Masaki Shiota
Journal of Molecular …, 2011
View PDFchevron_right
Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models
Vincent Njar
Cells
View PDFchevron_right
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Asish Pati
Frontiers in Oncology, 2020
View PDFchevron_right
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
Daniela Schuster
2020
View PDFchevron_right
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
Tonci Sustic
eLife, 2019
View PDFchevron_right
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Dean Tang
Nature communications, 2018
View PDFchevron_right
A Dominant-negative Mutant of Androgen Receptor Coregulator ARA54 Inhibits Androgen Receptor-mediated Prostate Cancer Growth
Mujib Rahman
Journal of Biological Chemistry, 2002
View PDFchevron_right
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
Guido Jenster, Wytske Van Weerden
PLoS ONE, 2010
View PDFchevron_right
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
Betsy Hirsch
Oncogene, 2012
View PDFchevron_right